Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ubrogepant in Migraine Patients on CGRP Monoclonal Antibodies (UNION)
NCT05503082Phase 4Active, not recruiting
- Sponsor
- Chicago Headache Center and Research Institute
- Start
- Sep 2022
- Primary completion
- Sep 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of ubrogepant in migraine, sponsored by Chicago Headache Center and Research Institute. Started Sep 2022; status: active, not recruiting.
02
Drugs
ubrogepant
03
Conditions
migraine
Beyond the preview
Go deeper on NCT05503082.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05503082.